Opus Genetics IRD Proceeds From Issuance In Connection With Registered Direct Offering
Proceeds From Issuance In Connection With Registered Direct Offering at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept ird:ProceedsFromIssuanceInConnectionWithRegisteredDirectOffering.
The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's proceeds from issuance in connection with registered direct offering.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Opus Genetics's proceeds from issuance in connection with registered direct offering?
- Opus Genetics (IRD) reported proceeds from issuance in connection with registered direct offering of $5.75M in Q4 2025.
- What does proceeds from issuance in connection with registered direct offering mean?
- Represents the gross cash proceeds received from the sale of equity securities through a registered direct offering. This is a vital metric for assessing the company's ability to access public capital markets to fund ongoing clinical trials. It highlights the company's success in securing external financing to extend its cash runway.